X

ASCO 2021: Updates in CAR-T

ASCO 2021: Updates in CAR-T

Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia

In a phase 1/2 trial, 8 of 11 patients with relapsed or refractory AML achieved a complete response with CAR T-cell therapy targeting C-type lectin-like molecule-1.

Cancer Therapy Advisor
06/06/2021
CAR-T Cell Therapy Shows Promise in Pretreated Patients With Multiple Myeloma

Ciltacabtagene autoleucel, a BCMA-targeting therapy, appears to show promising activity among patients with previously treated MM, per research presented at the 2021 ASCO Annual Meeting.

Hematology Advisor
06/06/2021
OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting

SHANGHAI, June 6, 2021 /PRNewswire/ -- On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) Co., Ltd. ("OriginCell"), together with Lishui Central Hospital affiliated to Zhejiang University and Shanghai Changzheng Hospital, presented the updated data from the on-going trial of Ori-CAR-001, a GPC3 CAR-T cell therapy for the treatment of relapsed/refractory hepatocellular carcinoma (HCC), at the 2021 annual meeting of American Society of Clinical Oncology. 

06/06/2021

Tecartus Demonstrates High Response Rate in Adults With R/R B-cell ALL Earning Priority Review Designation

Results of the primary analysis of Tecartus (brexucabtagene autoleucel) in adults with relapsed/refractory B-cell precursor ALL were simultaneously published in The Lancet and presented at

06/04/2021
Legend Biotech Announces New and Updated Data for Investigational BCMA CAR-T Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed or Refractory Multiple Myeloma at 2021 ASCO and EHA Meetings

Legend Biotech announced today that new and updated results for ciltacabtagene autoleucel (cilta-cel), an investigational BCMA-directed CAR-T therapy for R/R MM, will be featured at ASCO 2021 and a

06/01/2021
CBMG Holdings Announces Data from 2 CAR-T Clinical Studies Selected for Podium Presentations at the ASCO Annual Meeting

CBMG Holdings today announced the publication of 2 abstracts of CAR-T therapies for liquid tumors published in conjunction with the 2021 ASCO Annual Meeting.

06/01/2021
ASCO 2021: Off-the-Shelf Cell Therapy Inches Towards Reality

According to Allogene, lymphoma data being presented at ASCO show that its anti-CD19 CAR-T therapy, ALLO-501, is on a par with autologous rivals.

05/20/2021

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834